Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03834285
Other study ID # 238575
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date May 9, 2019
Est. completion date April 8, 2025

Study information

Verified date March 2020
Source King's College Hospital NHS Trust
Contact Joe Montebello
Phone 0203 299 5303
Email j.montebello@nhs.net
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Liver Diseases in pregnancy represents rare disorders and current data is derived primarily from single centres and retrospective cohorts. Moreover, the population prevalence of these diseases is low and to-date, it has proven difficult to generate reliable data at a patient level.

This is a multi-center, prospective cohort study that will open at 3 centers within the UK; and 4 centers in the European Union. The investigators will aim to collect data and blood samples at various time points, for patients presenting with liver disease during pregnancy. The main rationale behind this study is to establish a platform that enables detailed review of the outcomes of these rare diseases; to help classify and stratify patients according to risk and develop interventional studies and care pathways to improve overall outcome.


Description:

The objectives of the study are as follows:

Primary Objective:

To determine the characteristic physiological and biological changes exhibited by females who develop the following liver diseases during pregnancy.

- Acute fatty liver of pregnancy

- Severe cholestasis of pregnancy

- Severe HELLP syndrome/hypertensive disease

- Pre-existing cirrhosis and pregnancy This will be determined through analysis of the standard of care imaging (Liver Ultrasound and Transient Elastography) and blood results (liver function tests, white blood cells, platelets and scoring systems for assessing the severity of liver disease (ALBI, APRI, FIB4 and ELF scores). These results will be analysed over the course of the participant's pregnancy and again at delivery, to explore any particularly distinguishing parameter changes for each disease group.

Secondary Objectives

1. To determine the change in the reported quality of life of these participants either from diagnosis of pregnancy-associated liver disease or confirmation of pregnancy for pre-existing cirrhotic patients - up to 3 months' post-delivery.

2. To determine the mitochondrial DNA content of blood from patients with Acute Fatty Liver of Pregnancy.

3. Create an associated pan-European bio-resource (whole blood and serum) collection, which will offer an opportunity for ongoing collaborative translational research. Each participant will be given the option of donating additional research samples (15ml) of blood at each visit under the study for the bio-resource.

Data from cirrhotic patients will be collected from pre-pregnancy and during the first, second and third trimesters as well as at delivery and post-partum. Data from patients with AFLP/HELLP/ICP will be collected from pre-diagnosis, at first presentation of liver disease, at peak of liver disease, during the recovery period from peak liver disease as well as at delivery and post-partum.


Recruitment information / eligibility

Status Recruiting
Enrollment 100
Est. completion date April 8, 2025
Est. primary completion date April 8, 2024
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Female patients older than 18 years of age, willing and able to sign written informed consent.

2. Pregnant and presenting with any one of the following conditions (confirmed by local diagnosis):

- Acute fatty liver of pregnancy

- Severe cholestasis of pregnancy

- Severe HELLP syndrome /hypertensive disease

- Pre-existing cirrhosis and pregnancy

3. Able to provide written informed consent

4. Willing to provide access to records to necessary data can be collected.

5. Willing to complete additional quality of life questionnaires as per protocol.

6. Willing to consider donation of optional blood samples as per protocol.

Exclusion Criteria:

1. Unable to provide written informed consent

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
United Kingdom King's College Hospital NHS Foundation Trust London

Sponsors (2)

Lead Sponsor Collaborator
King's College Hospital NHS Trust European Association for the Study of the Liver

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Overall maternal and fetal health during pregnancy and post-delivery in females with liver disease Data from 100 patients will be collected across the EU who have either pre-exisiting cirrhosis or one of the three pregnancy-associated liver diseases that are to be studied in this protocol (AFLP, HELLP, ICP) Data to be collected from pre-pregnancy to 3 months post-delivery
See also
  Status Clinical Trial Phase
Recruiting NCT05793983 - S100A8/A9 and Innate Immunity in Liver Disease
Completed NCT04604860 - Use of EL-FIT App to Promote Physical Activity N/A
Recruiting NCT05928624 - A Pilot Trial to Test the Feasibility of Utilizing Home Blood Pressure Monitoring to Optimize the Administration of Midodrine Among Decompensated Cirrhosis Patients N/A
Active, not recruiting NCT01438970 - Effects of Treatment of Ascites by the ALFApump System on Renal and Circulatory Function Phase 2
Recruiting NCT05998330 - LiverPAL: A Trial of Inpatient Palliative Care for Patients With Advanced Liver Disease N/A
Completed NCT04581369 - Cirrhosis Medical Home N/A
Withdrawn NCT04244877 - Rifaximin's Effect on Covert Hepatic Encephalopathy With SIBO and Gastrointestinal Dysmotility Phase 3
Recruiting NCT04588077 - Comparison Between 2-dose Versus 3-dose Regimens of Heplisav B in Cirrhosis Phase 4
Recruiting NCT05538962 - Longitudinal Monitoring of Inflammation in Cirrhosis N/A
Completed NCT04082780 - Rifamycin in Minimal Hepatic Encephalopathy Phase 2
Completed NCT03850977 - Is There an Association Between Chronic Pancreatitis and Pulmonary Function
Active, not recruiting NCT03736265 - Carvedilol for Prevention of Esophageal Varices Progression N/A
Recruiting NCT04530760 - Intraabdominal Hypertension and Occurrence of Microaspiration in Cirrhotics Under Mechanical Ventilation
Recruiting NCT05093218 - Effect of Branch Chain Amino Acid Therapy on Sarcopenia in Children With Chronic Liver Disease. N/A
Recruiting NCT03437876 - Study on Effect of Intestinal Microbiota Transplantation in Hepatitis B Virus Induced Cirrhosis N/A
Recruiting NCT05604274 - Longitudinal Monitoring of Stool Characteristics
Recruiting NCT04867954 - Development of 4D Flow MRI for Risk Stratification of Variceal Bleeding in Cirrhosis
Completed NCT04643795 - Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses of MGL-3196 in Subjects With Varying Degrees of Hepatic Impairment and Healthy Matched Control Subjects Phase 1
Active, not recruiting NCT02344680 - Liver Fibrosis in Zambian HIV-HBV Co-infected Patients
Completed NCT04121520 - Perioperative Care of HVPG Measurement (CHESS1904): An International Multicenter Survey